Top

Published in:

01-07-2016 | Original Article

Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma

Authors: Kulthida Vaeteewoottacharn, Ryusho Kariya, Paweena Dana, Sawako Fujikawa, Kouki Matsuda, Koichi Ohkuma, Eriko Kudo, Ratthaphol Kraiklang, Chaisiri Wongkham, Sopit Wongkham, Seiji Okada

Published in: Tumor Biology | Issue 7/2016

Abstract

Cholangiocarcinoma (CCA) is a unique liver cancer subtype with an increasing incidence globally. The lack of specific symptoms and definite diagnostic markers results in a delayed diagnosis and disease progression. Systemic chemotherapy is commonly selected for advanced CCA even though its advantages remain unknown. Targeted therapy, especially anti-vascular endothelial growth factor (VEGF) therapy, is promising for CCA; however, improvements in the therapeutic regimen are necessary to overcome subsequent resistance. We demonstrated VEGF expression was higher in CCA cell lines than in other liver cancer cells. Secreted VEGFs played roles in the induction of peri- and intra-tumoral vascularization. VEGF neutralization by bevacizumab effectively reduced tumor growth, mainly through the suppression of angiogenesis; however, increases in the expression of hypoxia-inducible factor 1α (HIF1α) and HIF1α-responsive genes (such as VEGF, VEGFR1, VEGFR2, carbonic anhydrase (CA) IX and CAXII) indicated the potential for subsequent therapeutic resistance. Supplementation with a carbonic anhydrase inhibitor, acetazolamide, enhanced the anti-CCA effects of bevacizumab. Anti-angiogenesis and anti-proliferation were observed with the combination treatment. These results suggested a novel treatment strategy to overcome anti-angiogenesis resistance and the importance of “induced essentiality” in the treatment of CCA.

Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96. doi:10.1097/SLA.0b013e318176c4d3.CrossRefPubMed

Wongkham S, Silsirivanit A. State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13(Suppl):17–27.PubMed

Eckel F, Brunner T, Jelic S, Group EGW. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2010;21 Suppl 5:v65–69. doi:10.1093/annonc/mdq167.CrossRef

Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H, et al. Biliary tract cancer treatment: results from the biliary tract cancer statistics registry in Japan. J Hepato-Biliary-Pancreat Surg. 2002;9(5):569–75. doi:10.1007/s005340200076.CrossRef

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. doi:10.1056/NEJMoa0908721.CrossRefPubMed

Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–7. doi:10.1038/sj.bjc.6604628.CrossRefPubMedPubMedCentral

Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancer. 2011;3(2):2243–54. doi:10.3390/cancers3022243.CrossRef

Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–25. doi:10.1038/sj.bjc.6604129.CrossRefPubMed

Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009;51(1):93–101. doi:10.1016/j.jhep.2009.03.017.CrossRefPubMed

10.

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54. doi:10.1016/S1470-2045(09)70333-X.CrossRefPubMed

11.

Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442.CrossRefPubMedPubMedCentral

12.

Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190–200. doi:10.1172/JCI70212.CrossRefPubMedPubMedCentral

13.

Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Genome Med. 2011;3(8):55. doi:10.1186/gm271.CrossRefPubMedPubMedCentral

14.

McIntyre A, Harris AL (2015) Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO molecular medicine. doi:10.15252/emmm.201404271

15.

McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res. 2012;18(11):3100–11. doi:10.1158/1078-0432.CCR-11-1877.CrossRefPubMedPubMedCentral

16.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009;8(7):1867–77. doi:10.1158/1535-7163.MCT-09-0274.CrossRefPubMedPubMedCentral

17.

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72(7):1773–83. doi:10.1158/0008-5472.CAN-11-3831.CrossRefPubMedPubMedCentral

18.

Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer. 2013;132(1):29–41. doi:10.1002/ijc.27666.CrossRefPubMed

19.

Seubwai W, Kraiklang R, Wongkham C, Wongkham S. Hypoxia enhances aggressiveness of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2012;13(Suppl):53–8.PubMed

20.

Thongchot S, Yongvanit P, Loilome W, Seubwai W, Phunicom K, Tassaneeyakul W, et al. High expression of HIF-1α, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis. Asian Pac J Cancer Prev. 2014;15(14):5873–8.CrossRefPubMed

21.

Morine Y, Shimada M, Utsunomiya T, Imura S, Ikemoto T, Mori H, et al. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology. 2011;58(110–111):1439–44. doi:10.5754/hge11156.PubMed

22.

Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 2004;77(3):446–51. doi:10.1097/01.TP.0000110292.73873.25.CrossRefPubMed

23.

Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005;11(22):3392–7.CrossRefPubMedPubMedCentral

24.

Seubwai W, Vaeteewoottacharn K, Hiyoshi M, Suzu S, Puapairoj A, Wongkham C, et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. Cancer Sci. 2010;101(7):1590–5. doi:10.1111/j.1349-7006.2010.01572.x.CrossRefPubMed

25.

Gotoh K, Kariya R, Matsuda K, Hattori S, Vaeteewoottacharn K, Okada S. A novel EGFP-expressing nude mice with complete loss of lymphocytes and NK cells to study tumor-host interactions. Biosci Trends. 2014;8(4):202–5.CrossRefPubMed

26.

Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol. 2015;141(3):465–74. doi:10.1007/s00432-014-1842-9.CrossRefPubMed

27.

Robinson GS, Ju M, Shih SC, Xu X, McMahon G, Caldwell RB, et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 2001;15(7):1215–7.PubMed

28.

Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, et al. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radic Biol Med. 2013;65:778–88. doi:10.1016/j.freeradbiomed.2013.08.161.CrossRefPubMed

29.

Taura M, Kudo E, Kariya R, Goto H, Matsuda K, Hattori S, et al. COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization. J Virol. 2015;89(5):2643–58. doi:10.1128/JVI.03105-14.CrossRefPubMed

30.

Kariya R, Matsuda K, Gotoh K, Vaeteewoottacharn K, Hattori S, Okada S. Establishment of nude mice with complete loss of lymphocytes and NK cells and application for in vivo bio-imaging. In Vivo. 2014;28(5):779–84.PubMed

31.

Vaeteewoottacharn K, Kariya R, Matsuda K, Taura M, Wongkham C, Wongkham S, et al. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. J Cancer Res Clin Oncol. 2013;139(9):1551–62. doi:10.1007/s00432-013-1473-6.CrossRefPubMed

32.

Mokhtari RB, Kumar S, Islam SS, Yazdanpanah M, Adeli K, Cutz E, et al. Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. BMC Cancer. 2013;13:378. doi:10.1186/1471-2407-13-378.CrossRefPubMedPubMedCentral

33.

Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, et al. Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013;123(4):1732–40. doi:10.1172/JCI65385.CrossRefPubMedPubMedCentral

34.

Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24(3):349–56. doi:10.1097/MOG.0b013e3282fbf9b3.CrossRefPubMedPubMedCentral

35.

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of G. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69. doi:10.1136/gutjnl-2011-301748.CrossRef

36.

von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut. 2001;48(1):87–96.CrossRef

37.

McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB Off J Int Hepato Pancreato Biliary Assoc. 2011;13(5):309–19. doi:10.1111/j.1477-2574.2010.00286.x.CrossRef

Title: Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
Authors: Kulthida Vaeteewoottacharn
Ryusho Kariya
Paweena Dana
Sawako Fujikawa
Kouki Matsuda
Koichi Ohkuma
Eriko Kudo
Ratthaphol Kraiklang
Chaisiri Wongkham
Sopit Wongkham
Seiji Okada
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4785-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?

Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells

Erratum to: Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance

Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma

DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3

Keynote webinar | Spotlight on antibody–drug conjugates in cancer